There are no plans to make a specific assessment. NHS England\u2019s severe asthma collaborative is developing the capacity in severe asthma centres to streamline patient pathways for biologic therapy and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4527", "label" : {"_value" : "Biography information for Helen Whately"} } , "answeringMemberConstituency" : {"_value" : "Faversham and Mid Kent"} , "answeringMemberPrinted" : {"_value" : "Helen Whately"} , "dateOfAnswer" : {"_value" : "2022-12-12", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-12-12T12:31:10.967Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-12-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential correlation between the capacity in the severe asthma centre network and levels of uptake of severe asthma biologics in England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "104145"} , {"_about" : "http://data.parliament.uk/resources/1457274", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1457274/answer", "answerText" : {"_value" : "
No specific assessment has been made. NHS England and NHS Improvement\u2019s Severe Asthma Collaborative are developing the capacity of the severe asthma centres to streamline patient pathways to biologic therapy and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} , "dateOfAnswer" : {"_value" : "2022-04-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-04-25T16:24:35.267Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-04-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the findings of LOGEX\u2019s International Comparison Medicines Uptake 2021 report to NHS England & NHS Improvement, published in December 2021, what assessment his Department has made of the effect of the capacity available in the severe asthma centres on levels of uptake of severe asthma biologics.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "153958"} , {"_about" : "http://data.parliament.uk/resources/1456324", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1456324/answer", "answerText" : {"_value" : "
NHS England and NHS Improvement commissioned LOGEX and IVM to report on the current usage of the five highest health gain categories against 10 other similar European countries to understand national and international differences. While the LOGEX and IVM report did not investigate the reasons for differences in use of asthma biologics, the report demonstrated that use of biologics in England is increasing. The National Institute for Health and Care Excellence\u2019s recommendations include that physicians evaluate patients on biologics and halt treatment if the patient does not respond adequately.<\/p>
The report suggests that variation in the use of biologics in the population in England reflects documented differences in clinical practice. NHS Digital\u2019s innovation scorecard estimates report on the use of biologic medicines to treat severe asthma shows that the level of use in England is in line with the expectations of the National Institute for Health and Care Excellence\u2019s recommendations. The Accelerated Access Collaborative has undertaken a review of the patient\u2019s journey to the initiation of asthma biologic treatment in severe asthma centres. The findings are informing the development of a consensus clinical pathway for uncontrolled and severe asthma with recommended timelines and roles and responsibilities for healthcare professionals. The clinical pathway is due to be published shortly.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} , "dateOfAnswer" : {"_value" : "2022-04-19", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "151107"} , {"_value" : "151108"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-04-19T15:16:49.31Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-03-31", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Government's 2019 Voluntary Scheme for Branded Medicines Pricing and Access, what progress the Government has made in respect of severe asthma in attaining its objective of reaching the upper quartile of uptake for the five highest health gain categories; what assessment he has made of the viability of retaining that objective in respect of severe asthma; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "151109"} , {"_about" : "http://data.parliament.uk/resources/1348832", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1348832/answer", "answerText" : {"_value" : "
No specific assessment has been made of the effect of home delivery of asthma biologic medication on patient outcomes.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-08-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-08-27T10:41:59.263Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-07-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what has been the effect of home delivery of biologic medication for asthma patients on patient outcomes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"} } , "tablingMemberConstituency" : {"_value" : "Makerfield"} , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"} ], "uin" : "36618"} , {"_about" : "http://data.parliament.uk/resources/1331943", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1331943/answer", "answerText" : {"_value" : "
The Department, the Association of the British Pharmaceutical Industry (ABPI) and NHS England and NHS Improvement set the objective of reaching the upper quartile of uptake in relation to comparator countries for the five highest health gain categories during the first half of the Voluntary Scheme for Branded Medicines Pricing and Access, which was published in 2019. This objective is not intended as a target for the prescription of medicines. Medicines prescribing, including the highest health gain categories, remains a decision between the clinician and patient in line with guidance and recommendations made by National Institute for Health and Care Excellence.<\/p>
When selecting the countries for international comparison of uptake of the five highest health gain categories, NHS England and NHS Improvement looked for countries with similar health systems and populations to England. NHS England and NHS Improvement have commissioned an independent third party to develop an objective methodology to compare uptake rate between countries.<\/p>
The Accelerated Access Collaborative (AAC) worked closely with NHS England and NHS Improvement in the identification of potential five highest health gain categories for support through its Rapid Uptake Products programme. Following the open selection process, asthma biologics were selected for tailored support to increase their adoption in the National Health Service for the treatment of severe asthma as part of the 2021/22 programme. The Academic Health Science Networks are also providing leadership and support to NHS organisations to implement changes to transform severe asthma services locally and improve access to these medicines. Support for the programme will continue to be kept under review.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"} } , "answeringMemberConstituency" : {"_value" : "Charnwood"} , "answeringMemberPrinted" : {"_value" : "Edward Argar"} , "dateOfAnswer" : {"_value" : "2021-06-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "13945"} , {"_value" : "13946"} , {"_value" : "13947"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-22T15:59:20.607Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-06-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of extending the NHS Accelerated Access Collaborative's (AAC) rapid uptake programme for asthma biologic therapies in response to the impact of the covid-19 outbreak on the work of the AAC.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "13948"} , {"_about" : "http://data.parliament.uk/resources/823588", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/823588/answer", "answerText" : {"_value" : "
The Department has made no such estimate. FP10 prescriptions forms do not specify what clinical indication the medicine/device is being prescribed for, therefore the requested data is not collected.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-24T12:15:06.33Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an estimate of the average yearly cost to patients of paying for prescribed asthma medication.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/432", "label" : {"_value" : "Biography information for Helen Jones"} } , "tablingMemberConstituency" : {"_value" : "Warrington North"} , "tablingMemberPrinted" : [{"_value" : "Helen Jones"} ], "uin" : "123051"} , {"_about" : "http://data.parliament.uk/resources/514073", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/514073/answer", "answerText" : {"_value" : "
Information on National Health Service expenditure on drugs for the treatment of asthma1<\/sup> in primary and secondary care is shown in the table.<\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to specify the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of drugs that treated conditions other than asthma.<\/p> <\/p> <\/p> Cost of drugs for the treatment of asthma, England2<\/sup><\/p><\/td><\/tr> Year<\/p><\/td> Primary care (£ millions)<\/p><\/td> Secondary care (£ millions)<\/p><\/td> Combined total (£ millions)<\/p><\/td><\/tr> 2010<\/p><\/td> 952.4<\/p><\/td> 43.9<\/p><\/td> 999.3<\/p><\/td><\/tr> 2011<\/p><\/td> 968.5<\/p><\/td> 45.1<\/p><\/td> 1,013.6<\/p><\/td><\/tr> 2012<\/p><\/td> 1,007.5<\/p><\/td> 49.0<\/p><\/td> 1,056.5<\/p><\/td><\/tr> 2013<\/p><\/td> 1,018.3<\/p><\/td> 52.4<\/p><\/td> 1,070.7<\/p><\/td><\/tr> 2014<\/p><\/td> 1,031.2<\/p><\/td> 56.1<\/p><\/td> 1,087.2<\/p><\/td><\/tr> 2015 3<\/sup><\/p><\/td> 1,039.4<\/p><\/td> -<\/strong><\/p><\/td> -<\/strong><\/p><\/td><\/tr><\/tbody><\/table> <\/p> Sources:<\/em> Prescription Cost Analysis (PCA) system data provided by the Health and Social Care Information Centre (primary care). Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care).<\/p> <\/p> Notes:<\/em><\/p> 1 <\/sup>Drugs for the treatment of asthma have been defined as those included in the following British National Formulary (BNF) sections, using the classification system prior to edition 70:<\/p> 3.1.1 Adrenoceptor agonists<\/p> 3.1.2 Antimuscarinic bronchodilators<\/p> 3.1.3 Theophylline<\/p> 3.2 Corticosteroids<\/p> 3.3.1 Cromoglicate and related therapy<\/p> 3.3.2 Leukotriene receptor antagonists<\/p> 3.4.2 Allergen immunotherapy (omalizumab only)<\/p> 2<\/sup> Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> 3<\/sup> Secondary care data for 2015 is not yet available.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2016-04-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-04-25T13:04:35.577Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-04-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much was spent by the NHS on asthma drugs in each year since 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/429", "label" : {"_value" : "Biography information for Derek Twigg"}
}
, "tablingMemberConstituency" : {"_value" : "Halton"}
, "tablingMemberPrinted" : [{"_value" : "Derek Twigg"}
], "uin" : "34586"}
, {"_about" : "http://data.parliament.uk/resources/386284", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/386284/answer", "answerText" : {"_value" : " We have made no such assessment. The National Institute for Health and Care Excellence (NICE) is responsible for providing guidance to the National Health Service on the clinical and cost effectiveness of selected drugs and indications through its technology appraisal programme. NICE has published several pieces of technology appraisal guidance covering a number of different technologies for use in the treatment of adults and children with asthma. Further information is available on NICE\u2019s website at:<\/p> <\/p> <\/p> <\/p>